Molnupiravir N-1 CAS 2346620-55-9 COVID-19 Ogo dị elu
Mbubata Azụmahịa Molnupiravir na ndị emetụtara nwere ogo dị elu
Uridine CAS 58-96-8
Cytidine CAS 65-46-3
Molnupiravir N-1 CAS 2346620-55-9
Molnupiravir (EIDD-2801) CAS 2349386-89-4
| Aha Chemical | Molnupiravir N-1 |
| Ụdị okwu | ((3aR,4R,6R,6aR) -6-((E) -4- (hydroxyimino) -2-oxo-3,4-dihydropyrimidin-1 (2H) -yl) -2,2-dimethyltetrahydrofuro[3, 4-d [1,3] dioxol-4-yl) methyl isobutyrate;Molnupiravir Intermediate;Molnupiravir Dimethyl Dioxol adịghị ọcha;Molnupiravir adịghị ọcha 11 |
| Nọmba CAS | 2346620-55-9 |
| Nọmba CAT | RF-PI310 |
| Ọnọdụ Ahịa | Na Akụrụngwa, Mpụta Ihe ruru narị narị kilograms |
| Usoro ihe omimi | C16H23N3O7 |
| Ibu molekụla | 369.37 |
| Solubility | Soluble na DMSO |
| Njupụta | 1.51±0.1 g/cm3 |
| Mbupu okpomọkụ | Ambient |
| Ụdị | Ruifu Chemical |
| Ihe | Nkọwapụta |
| Ọdịdị | Ọcha ka Gbanyụọ-Ọcha ntụ ntụ |
| Ọnwụ na ihicha | ≤1.0% |
| Ihe fọdụrụ na mgbanye | ≤0.20% |
| Otu adịghị ọcha | ≤0.50% |
| Mgbakọta adịghị ọcha | ≤2.0% |
| Ọla dị arọ | ≤20ppm |
| Ịdị ọcha | ≥98.0% |
| Nlele ọkọlọtọ | Standardkpụrụ ụlọ ọrụ |
| Ojiji | Ọkara nke Molnupiravir (CAS 2349386-89-4) COVID-19 |
ngwugwu: Kalama, Aluminom foil bag, kaadiboodu drum, 25kg / Drum, ma ọ bụ dị ka ndị ahịa chọrọ.
Ọnọdụ Nchekwa:Na-echekwa n'ime akpa ndị a kpuchiri ekpuchi na ebe dị jụụ na nke kpọrọ nkụ;Chebe site na ọkụ, mmiri mmiri na ụmụ ahụhụ.
Molnupiravir N-1 (CAS 2346620-55-9), bụ etiti Molnupiravir (CAS 2349386-89-4) na ọgwụgwọ COVID-19.Molnupiravir (EIDD-2801) bụ ọnụọgụ ọnụ nke enwere ike ịnweta analog ribonucleoside nke na-egbochi mmegharị nke ọtụtụ nje RNA gụnyere SARS-CoV-2, onye na-akpata COVID-19.EIDD-2801 (7 mg/kg; po; ugboro abụọ kwa ụbọchị maka ụbọchị 3.5) na-ebelata ibu nje a wụsara na ogologo oge nke ahụ ọkụ.Molnupiravir (EIDD-2801) na-arụ ọrụ nke ọma na vivo mgbe ọ gbasasịrị, na-eme ka a chọpụta naanị NHC n'efu na plasma.EIDD-2801 gbasiri ike na-ebelata MERS-CoV na-efe efe titers, nje virus RNA, na pathogenesis n'okpuru ma prophylactic na mmalite ọgwụgwọ ọnọdụ.Molnupiravir (EIDD-2801, MK-4482) bụ ọgwụ a na-ahụ maka ọnụ nke ribonucleoside analogue β-d-N4-hydroxycytidine (NHC; EIDD-1931) nwere nnukwu ọrụ mgbochi nje megide SARS-CoV-2, MERS-CoV, SARS-CoV, na onye na-akpata COVID-19.
